DelveInsight's "Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Nonmelanoma, epidemiology insights, Merkel Cell Carcinoma market trends, therapies, and key companies working in the Nonmelanoma Market in 7MM.
Nonmelanoma Skin Cancer Overview
The skin is made of a variety of cells, many of which are in constant motion. Round basal cells below the surface flatten as they rise to replace dead, flaking squamous cells on the surface. Melanocytes tan the skin in the sunlight, and Merkel cells give the skin its ability to sense touch. When these cells become damaged, they may develop into skin cancer. Skin cancer can be further classified into melanoma and nonmelanoma. Skin cancers that are not melanomas are sometimes grouped as nonmelanoma skin cancers because they develop from skin cells other than melanocytes. They tend to behave very differently from melanomas and are often treated with different methods. Several types of skin cancer fall within the broader category of nonmelanoma skin cancer, but the primary forms are basal cell carcinoma and squamous cell carcinoma.
Nonmelanoma Skin Cancer Epidemiology Insight
-
According to Cedars-Sinai (n.d.), Skin cancer is the most common of all cancers. Between 40 and 50% of all cancer cases diagnosed every year are skin cancer. After treatment, basal cell carcinoma may grow again on the same spot or appear elsewhere on the skin. Between 35 and 50% of people who develop one basal cell carcinoma will grow a new skin cancer within five years of diagnosis.
-
Akdeniz et al. (2019) conducted a representative multicenter prevalence study in a random sample of ten institutional long-term care facilities in the federal state of Berlin, Germany. Nonmelanoma skin cancer was diagnosed in 7.2% of patients, and 6.7% of patients were also found to have basal cell carcinoma.
Click here to learn more about the Nonmelanoma Skin Cancer Market Landscape
The Report Covers the Nonmelanoma Skin Cancer Epidemiology Segmented by:
-
Total Nonmelanoma Skin Cancer prevalent cases
-
Total Nonmelanoma Skin Cancer diagnosed prevalent cases
-
Total Nonmelanoma Skin Cancer gender-specific diagnosed prevalent cases
-
Total Nonmelanoma Skin Cancer age-specific diagnosed prevalent cases
Nonmelanoma Skin Cancer Market Outlook
Nonmelanoma Skin Cancer treatment is determined on a case-by-case basis, depending on many factors, such as the type and stage of cancer, the size and location of the tumor, and the patient’s medical history and overall health.
Nonsurgical treatments, such as freezing (cryotherapy), anti-cancer creams, photodynamic therapy, radiotherapy, and electrochemotherapy, are also used in certain circumstances.
Nonmelanoma Skin Cancer coverage and support are one of the major drivers fueling growth in the non-melanoma skin cancer market. Direct medical expenses for treating Nonmelanoma skin cancer include pathology fees, facility fees, diagnosis fees, treatment fees, repair fees, and other incidentals. Medicare and the majority of payers reimburse the costs of surgeries as part of treatment. Compared to surgery, the majority of pharmacological techniques demand significant effort and several doctor visits. Most of the medications for Nonmelanoma Skin Cancer are paid for by the manufacturing business in the form of patient support and discount vouchers for low-income populations.
Vismodegib is used for metastatic BCC or locally advanced BCC when surgery or radiation therapy cannot be used. Vismodegib is given daily as a pill by mouth (orally). It is usually given as long as the drug is working or unless the side effects outweigh the treatment benefits.
Key Companies Working in the Nonmelanoma Skin Cancer Market
-
OncoBeta Therapeutics
-
Pfizer
-
Galderma
-
Bristol Myers Squibb
-
Sanofi
And many others
Nonmelanoma Skin Cancer Therapies Covered and Analyzed in the Report:
-
Voriconazole
-
SRT-100
-
IFx-Hu
-
Nivolumab
-
Relatlimab
And many others
Learn more about the Key Companies and Emerging Therapies in the Nonmelanoma Skin Cancer Market
Table of Contents
-
Key Insights
-
Nonmelanoma Skin Cancer Introduction
-
Executive Summary of Nonmelanoma Skin Cancer
-
Disease Background and Overview
-
Epidemiology and patient population
-
Nonmelanoma Skin Cancer Emerging Therapies
-
Nonmelanoma Skin Cancer Market Outlook
-
Nonmelanoma Skin Cancer Market Access and Reimbursement of Therapies
-
Nonmelanoma Skin Cancer Market Drivers
-
Nonmelanoma Skin Cancer Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Nonmelanoma Skin Cancer Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
